# US 11,110,141 B2 · Herbal compositions for the prevention or treatment of urinary incontinence and overactive bladder

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,110,141 B2
- Document ID: US11110141B2
- Status: Granted
- Kind: B2
- Application number: 15/261,021
- Filed: 2016-09-09
- Published: 2016-12-29
- Granted: 2021-09-07
- Earliest claimed: 2011-12-23
- Assignees: Rox IP Pty Ltd.
- Applicants: Tracey Anne Seipel
- Inventors: Tracey Anne Seipel
- Web page: https://patentgrep.com/patent/US11110141B2

## CPC

- A61K 36/54: Lauraceae (Laurel family), e.g. cinnamon or sassafras
- A61K 36/11: Pteridophyta or Filicophyta (ferns)
- A61K 36/12: Filicopsida or Pteridopsida
- A61K 36/185: Magnoliopsida (dicotyledons)
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 13/10: of the bladder
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided in one embodiment is an herbal compositions for the prevention or treatment of urogenital system disorders including urinary incontinence, overactive bladder, enuresis, benign prostatic hyperplasia, nocturia, cystitis, urinary calculi, or a urinary tract infection. Specifically one embodiment provides compositions that contain Crateva nurvala, Equisetum arvense, and Lindera aggregata and methods of use thereof.

## Claims

### Claim 1

An herb for treating or reducing the symptoms of urinary incontinence or overactive bladder comprising effective amounts of:
(i) a Crateva nurvala extract preparation;
(ii) an Equisetum arvense extract preparation; and
(iii) a Lindera aggregata extract preparation;
wherein the herb-containing composition is formulated as an oral dosage unit whereby the oral dosage unit is in a form selected from a tablet, capsule or caplet.

### Claim 2 (depends on 1)

The herb-containing composition of claim 1, wherein the Crateva nurvala extract preparation is standardized to have lupeol content not less than 1.5% and tannin content not less than 2% based on the total weight of the standardized Crateva nurvala extract preparation.

### Claim 3 (depends on 1)

The herb-containing composition of claim 1, wherein the Equisetum arvense extract preparation is standardized to have lupeol content not less than 1.5% and tannin content not less than 2% based on the total weight of the standardized Equisetum arvense extract preparation.

### Claim 4 (depends on 1)

The herb-containing composition of claim 1, wherein the Lindera aggregata extract preparation is standardized to have lupeol content not less than 1.5% and tannin content not less than 2% based on the total weight of the standardized Lindera aggregata extract preparation.

### Claim 5 (depends on 1)

The herb-containing composition of claim 1, wherein the Crateva nurvala extract preparation is present at a concentration from about 1 g to about 18 g dry weight equivalents per oral dosage unit.

### Claim 6 (depends on 1)

The herb-containing composition of claim 1, wherein the Equisetum arvense extract preparation is present at a concentration from about 750 mg to about 12 g dry weight equivalents per oral dosage unit.

### Claim 7 (depends on 1)

The herb-containing composition of claim 1, wherein the Lindera aggregata extract preparation is present at a concentration from about 750 mg to about 12 g dry weight equivalents per oral dosage unit.

### Claim 8 (depends on 1)

The herb-containing composition of claim 1, wherein at least one of the extract is as follows:
(i) the Crateva nurvala extract preparation is a bark extract preparation;
(ii) the Equisetum arvense extract preparation is a stem extract preparation; and
(iii) the Lindera aggregata extract preparation is a root extract preparation.

### Claim 9 (depends on 1)

The herb-containing composition of claim 1, wherein the oral dosage unit is formulated as a controlled-release vehicle.

### Claim 10 (depends on 1)

A pharmaceutical composition comprising the herb-containing composition of claim 1 and a pharmaceutically-acceptable carrier.

### Claim 11

An herb for treating or reducing the symptoms of urinary incontinence or overactive bladder comprising effective amounts of:
(i) a Crateva nurvala bark extract preparation;
(ii) an Equisetum arvense stem extract preparation;
(iii) a Lindera aggregata root extract preparation;
wherein the herb-containing composition is formulated as an oral dosage unit, whereby the oral dosage unit is in a form selected from a tablet, capsule or caplet, and wherein the Equisetum arvense stem extract preparation and the Lindera aggregata root extract preparation are present at the same concentration.

### Claim 12 (depends on 11)

A pharmaceutical composition comprising the herb-containing composition of claim 11 and a pharmaceutically-acceptable carrier.